Tenax Therapeutics, Inc.

TENX

Exchange: Nasdaq
Industry: Pharmaceutical Preparations
SEC CIK: 0000034956

SEC filings (opens in a new tab)

In the last 90 days, Tenax Therapeutics, Inc. insiders filed 7 open-market purchases and 0 sales; 111 institutions reported holding it in 13F filings for Q2 2026, worth $441.4M in total; no superinvestor holds it.

Key figures

Market capClose on Nov 10, 2026: $77.0M
Insider buysLast 90 days, $6.40M in total: 7
Insider sellsOpen market, last 90 days: 0
13F holdersQ2 2026, +31 vs. previous quarter: 111
13F valueReported value at the end of Q2 2026: $441.4M
Superinvestors holdingAt the end of Q2 2026: 0

Price chart

Chart by TradingView (opens in a new tab)

Financials

See financial statements

From SEC filings, in USD.

Revenue, FY2025: $0; No comparable prior period
Net income, FY2025: -$52.6M; No comparable prior period
Free cash flow, FY2025: –; No comparable prior period
Revenue, Q3 FY2026: $0; No comparable prior period

Short interest

See short data

From FINRA, settlement date Oct 15, 2026.

Short interest: 7.23M; Shares sold short
Change: +47.1K; +0.7% vs. previous
Days to cover: 3.22; At average daily volume

Superinvestors holding TENX, Q2 2026

Go to the superinvestors tab

No superinvestor reported holding TENX at the end of Q2 2026.

Latest insider trades

See all insider trades

Open-market purchases and sales by Tenax Therapeutics, Inc. insiders from Form 4, newest first.

Insider trades
Filed (ET)	Trade date	Filing delay	Insider	Transaction	Shares	Avg price	Value	Holding change	Flags
Oct 21, 2026 (view filing)4:49 PM ET	Oct 19-21	2 days	Schneeberger Daniel and 1 other10% Owner	PPurchase	+922.8K	$1.59	+$1.46M	+14.1%7.45M after	3 lots
Sep 17, 2026 (view filing)9:30 PM ET	Sep 16	1 day	Doogan DeclanDirector	PPurchase	+53.0K	$1.92	+$101.8K	+2,330.7%55.3K after
Sep 15, 2026 (view filing)9:38 PM ET	Sep 11-15	4 days	Giordano Christopher ThomasCEO	PPurchase	+10.8K	$1.85	+$20.1K	+95.8%22.2K after	2 lots
Sep 15, 2026 (view filing)9:30 PM ET	Sep 11	4 days	Staab Thomas R IIChief Financial Officer	PPurchase	+5.67K	$1.94	+$11.0K	+56.8%15.7K after
Sep 8, 2026 (view filing)5:16 PM ET	Sep 3	5 days	Schneeberger Daniel and 1 other10% Owner	PPurchase	+900.0K	$1.78	+$1.60M	+16.0%6.52M after
Sep 2, 2026 (view filing)5:52 PM ET	Aug 31-Sep 2	2 days	Schneeberger Daniel and 1 other10% Owner	PPurchase	+770.3K	$1.79	+$1.38M	+15.9%5.62M after	3 lots
Aug 24, 2026 (view filing)6:12 PM ET	Aug 20-24	4 days	Schneeberger Daniel and 1 other10% Owner	PPurchase	+1.03M	$1.77	+$1.81M	+26.8%4.85M after	3 lots
Dec 10, 2025 (view filing)	Dec 8	2 days	Rich StuartChief Medical Officer	PPurchase	+2.50K	$10.10	+$25.3K	+100.0%5.00K after
Dec 10, 2025 (view filing)	Dec 9	1 day	Rich StuartChief Medical Officer	PPurchase	+2.50K	$10.22	+$25.6K	+90.4%5.27K after
Dec 5, 2025 (view filing)	Dec 2-3	3 daysLate	Rich StuartChief Medical Officer	PPurchase	+2.50K	$9.05	+$22.6K	+939.8%2.77K after	2 lots

Top 10 13F holders, Q2 2026

See all 111 holders

The largest institutional positions in Tenax Therapeutics, Inc. at the end of Q2 2026; share changes are against Q1 2026.

Institutions holding TENX in Q2 2026
Institution	Shares	Value	% of portfolio	Change in shares	Action
FMR LLC	3,942,373	$57.4M	0.00%	+3,619,773+1,122.1%	Added
Vivo Capital, LLC	2,500,000	$36.4M	3.32%	+2,291,667+1,100.0%	Added
BlackRock, Inc.	1,727,988	$25.1M	0.00%	+1,711,011+10,078.4%	Added
Perceptive Advisors LLC	1,700,000	$24.7M	0.38%	+252,218+17.4%	Added
Vanguard Capital Management LLC	1,147,121	$16.7M	0.00%	+883,700+335.5%	Added
Millennium Management LLC	876,230	$12.7M	0.01%	+342,341+64.1%	Added
Ikarian Capital, LLC	787,600	$11.5M	1.88%	−230,000−22.6%	Reduced
Candriam Luxembourg S.C.A.	749,588	$10.9M	0.05%	+749,588	New
Citadel Advisors LLC	728,561	$10.6M	0.01%	+576,045+377.7%	Added
RTW Investments, LP	696,570	$10.1M	0.09%	+326,324+88.1%	Added

Holders of 5% or more of TENX

See all 10 holders and filings

Holders whose latest Schedule 13D or 13G filing reports 5% or more of Tenax Therapeutics, Inc..

Largest holders of TENX from 13D and 13G filings
Holder	Latest form	Stake	Change	First filed	Latest filing	Filing
ADAR1 Capital Management, LLC	13G	14.00%5.26M shares	New	Sep 8, 20261 filing	Sep 8, 2026	SEC
Biotechnology Value Fund L P	13G/A	9.99%3.11M shares	0.00 ppfrom 9.99%	Aug 19, 20244 filings	Aug 14, 2026	SEC
Janus Henderson Group PLC	13G	9.99%623.7K shares	+5.99 ppfrom 4.00%	Aug 14, 20246 filings	Dec 8, 2025	SEC
RTW Investments, LP	13G/A	9.90%2.87M shares	0.00 ppfrom 9.90%	May 15, 20254 filings	Aug 14, 2026	SEC
Vestal Point Capital, LP	13G	9.90%2.47M shares	New	Nov 14, 20251 filing	Nov 14, 2025	SEC